Cell therapy weekly: first COVID-19 patient dosed with allogeneic iNKT cell therapy

This week: Agenus has announced the dosing of the first COVID-19 patient with their allogeneic iNKT cell therapy, a USD$50 million program has been announced to bioengineer human organ systems, and Minaris Regenerative Medicine significantly expands their cell and gene manufacturing capacity in Europe and Asia. The news headlines: First COVID-19 patient dosed with allogeneic iNKT cell therapy HOPE: USD$50 million program announced to bioengineer human organ systems Minaris Regenerative Medicine significantly expands cell and gene therapy manufacturing capacity   First COVID-19 patient dosed with allogeneic iNKT cell therapy Agenus (MA, USA) has announced the dosing of the first COVID-19...